Emisphere’s Oral Insulin Product Candidate

• Favorable kinetics consistently demonstrated

• Delivers unaltered insulin

• EMISPHERE® delivery agent

manufacturing scaled up

Oral Insulin

• Potential first line therapy for Type 2 diabetes
  • ADA presentation of data in Type 2 patients in June

Previous slide

Next slide

Back to first slide

View graphic version